"iDoctor – Medical Blog"

Background:
HIV-1 integrase (IN) is an attractive target for the development of drugs to treat AIDS, and inhibitors of this viral enzyme are already in the clinic. Nevertheless, there is a continuing need to devise new approaches to block the activity of this viral protein because of the emergence of resistant strains. To facilitate the biochemical analysis of wild-type IN and its derivatives, and to measure the potency of prospective inhibitory compounds, a rapid, moderate throughput solution assay was developed for IN-catalyzed joining of viral and target DNAs, based on the detection of a fluorescent tag.
Results:
A detailed, step-by-step description of the new joining assay is provided. The reactions are run in solution, the products captured on streptavidin beads, and activity is measured by release of a fluorescent tag. The procedure can be scaled up for the analysis of numerous samples, and is substantially more rapid and sensitive than the standard radioactive gel methods. The new assay is validated and its utility demonstrated via a detailed comparison of the Mg++- and Mn++-dependent activities of the IN proteins from human immunodeficiency virus type 1 (HIV-1) and the avian sarcoma virus (ASV). The results confirm that ASV IN is considerably more active than HIV IN, but with both enzymes the initial rates of joining, and the product yields, are higher in the presence of Mn++ than Mg++. Although the pH optima for these two enzymes are similar with Mn++, they differ significantly in the presence of Mg++, which is likely due to differences in the molecular environment of the binding region of this physiologically relevant divalent cation. This interpretation is strengthened by the observation that a compound that can inhibit HIV-1 IN in the presence of either metal cofactors is only effective against ASV in the presence of Mn++.
Conclusion:
A simplified, assay for measuring the joining activity of retroviral IN in solution is described, which offers several advantages over previous methods and the standard radioactive gel analyses. Based on comparisons of signal to background ratios, the assay is 10-30 times more sensitive than gel analysis, allows more rapid and accurate biochemical analyses of IN catalytic activity, and moderate throughput screening of inhibitory compounds. The assay is validated, and its utility demonstrated in a comparison of the metal-dependent activities of HIV and ASV IN proteins.

HOUSTON (MedPage Today) — Studies examining a possible cancer link to insulin glargine (Lantus) produced mixed conclusions that drew quick, reassuring messages from diabetes authorities.

SAN FRANCISCO (MedPage Today) — Widespread prostate cancer screening substantially increases diagnoses without much evidence for a survival benefit, a review found.

DALLAS (MedPage Today) — Obesity surgery led to substantial weight loss and resolution of comorbidities in a small group of patients whose body mass index did not meet current criteria for the surgery.

SAN FRANCISCO (MedPage Today) — Golimumab (Simponi) alleviates rheumatoid arthritis symptoms in patients who have previously received another tumor necrosis factor-alpha inhibitor, researchers found.

LITTLE FALLS, N.J. (MedPage Today) — The new H1N1 flu virus has the ability to cause serious illness and death among young individuals with no preexisting medical conditions, Mexican researchers confirmed.

WHEELING, W.Va. (MedPage Today) — Studies of cancer drugs that are expected to find survival advantages of two months or less should be undertaken only if the treatment costs less than $20,000, two NIH researchers recommended.

ATLANTA (MedPage Today) — Zanamivir (Relenza) should be the preferred treatment for patients with influenza-like illness, whether infection is caused by a seasonal virus or the pandemic H1N1 virus, an advisory committee to the CDC said.

ATLANTA (MedPage Today) — At least one million people in the U.S. have been infected with the new H1N1 flu virus, according to preliminary findings from the CDC.

LITTLE FALLS, N.J. (MedPage Today) — The new H1N1 flu virus has the ability to cause serious illness and death among young individuals with no preexisting medical conditions, Mexican researchers confirmed.